LU92033I9 - - Google Patents

Info

Publication number: LU92033I9
Authority: LU; Luxembourg
Prior art keywords: sub; atoms; nitrogen; formula; fused
Prior art date: 2001-07-31

Application number

LU92033C

Other languages

English (en)

Other versions

LU92033I2 (fr

Inventor

Gary J Bridger

Michael J Abrams

Geoffrey W Henson

Ronald Trevor Macfarland

Gary B Calandra

C David Dale

Hal E Broxmeyer

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2012-06-27

Publication date

2019-01-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92033(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-27 Application filed by Genzyme Corp filed Critical Genzyme Corp

2012-08-27 Publication of LU92033I2 publication Critical patent/LU92033I2/fr

2019-01-03 Publication of LU92033I9 publication Critical patent/LU92033I9/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LU92033C 2001-07-31 2012-06-27 Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) LU92033I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US30919601P	2001-07-31	2001-07-31
US38215502P	2002-05-20	2002-05-20
PCT/US2002/024212 WO2003011277A2 (fr)	2001-07-31	2002-07-30	Methodes de mobilisation de cellules souches/embryonnaires

Publications (2)

Publication Number	Publication Date
LU92033I2 LU92033I2 (fr)	2012-08-27
LU92033I9 true LU92033I9 (fr)	2019-01-03

Family

ID=26976666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU92033C LU92033I2 (fr)	2001-07-31	2012-06-27	Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Country Status (28)

Country	Link
US (9)	US6987102B2 (fr)
EP (3)	EP2371361B1 (fr)
JP (2)	JP5137288B2 (fr)
KR (2)	KR20040020075A (fr)
CN (2)	CN102302493B (fr)
AT (1)	ATE538785T1 (fr)
AU (1)	AU2002318927B2 (fr)
BE (1)	BE2019C544I2 (fr)
BR (1)	BRPI0211570B8 (fr)
CA (1)	CA2455559C (fr)
CY (4)	CY1112633T1 (fr)
DK (2)	DK1411918T3 (fr)
ES (2)	ES2380009T3 (fr)
FR (2)	FR12C0042I1 (fr)
HU (1)	HUP0402360A2 (fr)
IL (2)	IL159312A0 (fr)
LT (2)	LT2371361T (fr)
LU (2)	LU92033I2 (fr)
MX (1)	MXPA04000982A (fr)
NL (2)	NL300537I2 (fr)
NO (4)	NO336989B1 (fr)
NZ (1)	NZ530169A (fr)
PL (1)	PL364673A1 (fr)
PT (2)	PT1411918E (fr)
RU (1)	RU2309741C2 (fr)
SI (2)	SI1411918T1 (fr)
WO (1)	WO2003011277A2 (fr)
ZA (1)	ZA200400658B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102302493B (zh) *	2001-07-31	2015-08-12	健赞股份有限公司	活化祖细胞/干细胞的方法
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
US7354932B2 (en)	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2002357379A1 (en)	2001-12-21	2003-07-15	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR101160698B1 (ko) *	2003-06-27	2012-06-28	아사히 가세이 가부시키가이샤	세포 분화 억제제, 이것을 이용하는 세포 배양 방법, 배양 배지 및 배양된 세포주
WO2005002522A2 (fr) *	2003-06-30	2005-01-13	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Compositions et methodes pour traiter une ischemie tissulaire
JP2007535479A (ja)	2003-08-13	2007-12-06	チルドレンズホスピタルメディカルセンター	ＧＴＰａｓｅを調節するためのキメラペプチド
US7417026B2 (en)	2003-08-13	2008-08-26	Children's Hospital Medical Center	Mobilization of hematopoietic cells
IL158868A0 (en) *	2003-11-13	2004-05-12	Yeda Res & Dev	Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (fr) *	2004-04-20	2005-11-03	Bayer Healthcare Ag	Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4)
CN101094684A (zh) *	2004-08-13	2007-12-26	阿诺麦德股份有限公司	用趋化因子的组合活化祖细胞/干细胞
US7785582B2 (en) *	2004-09-07	2010-08-31	Johnson Lanny L	Use of synovium and omentum for tissue engineering
US8182806B2 (en) *	2004-09-07	2012-05-22	Johnson Lanny L	Synovial villi for use with tissue engineering
EP1814587A2 (fr)	2004-11-05	2007-08-08	The General Hospital Corporation	Eloignement volontaire de cellules migratoires humaines d'une source d'agents
PT1904084E (pt)	2005-06-13	2013-07-22	Cleveland Clinic Foundation	Métodos de proteção contra apoptose mediante uso de lipopéptidos
EP1951046B1 (fr) *	2005-08-19	2012-07-18	Genzyme Corporation	Methodes permettant d'augmenter l'efficacite d'une chimiotherapie
EP1924606A4 (fr) *	2005-08-25	2010-01-13	Repair Technologies Inc	Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
US8518349B2 (en)	2005-09-12	2013-08-27	Lanny Johnson	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US7927630B2 (en) *	2005-09-12	2011-04-19	Johnson Lanny L	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) *	2005-11-18	2007-05-24	Rensselaer Polytechnic Institute	Stem cells within gel microenvironments
US20100035941A1 (en) *	2006-02-24	2010-02-11	Bridger Gary J	Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (fr) *	2006-03-21	2007-09-27	Stichting Skeletal Tissue Engineering	Nouveau procede d'induction de la differenciation de cellules souches et progenitrices
CN101500595A (zh) *	2006-08-07	2009-08-05	健赞股份有限公司	组合治疗
US7883698B2 (en) *	2007-01-17	2011-02-08	Maria Michejda	Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) *	2008-08-29	2011-10-06	Genzyme Corporation	Cxcr4 antagonists for kidney injury
US20130039882A1 (en) *	2009-10-28	2013-02-14	Henry Ford Health System	Method to mitigate injury from radiation exposure
CN101716167B (zh) *	2009-12-08	2011-12-28	中国人民解放军军事医学科学院野战输血研究所	一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
EP2600901B1 (fr)	2010-08-06	2019-03-27	ModernaTX, Inc.	Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
KR20210094672A (ko)	2011-05-16	2021-07-29	젠자임 코포레이션	Ｃｘｃｒ４ 길항제의 용도
EP2968563A4 (fr) *	2013-03-15	2016-11-30	Leonard B Miller	Traitement combiné pour améliorer la cicatrisation de tissu mou, la cicatrisation de greffe de tissu adipeux, la cicatrisation osseuse endochondrale et l'ostéointégration
US9988973B2 (en)	2015-01-06	2018-06-05	Hamilton Sundstrand Corporation	Water injector for aviation cooling system
EP3349797A4 (fr)	2015-09-18	2019-06-12	The General Hospital Corporation Dba Massachusetts General Hospital	Apport localisé d'un agent antichimiorépulsion pour le traitement du cancer
JP6958820B2 (ja)	2015-12-14	2021-11-02	エックス４ファーマシューティカルズ，インコーポレイテッド	がんを処置する方法
CA3008272A1 (fr)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methodes de traitement du cancer
EP3389720A1 (fr)	2015-12-18	2018-10-24	The General Hospital Corporation	Polymères polyacétal, conjugués, particules et utilisations associées
JP7055380B2 (ja)	2015-12-22	2022-04-18	エックス４ファーマシューティカルズ，インコーポレイテッド	免疫不全疾患を処置するための方法
US11337969B2 (en)	2016-04-08	2022-05-24	X4 Pharmaceuticals, Inc.	Methods for treating cancer
WO2017216373A1 (fr) *	2016-06-16	2017-12-21	Centre National De La Recherche Scientifique	Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
CN109641838A (zh)	2016-06-21	2019-04-16	X4 制药有限公司	Cxcr4抑制剂及其用途
CN116554168B (zh)	2016-06-21	2025-09-23	X4制药有限公司	Cxcr4抑制剂及其用途
WO2017223229A1 (fr)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
WO2018049120A1 (fr)	2016-09-09	2018-03-15	The General Hospital Corporation	Cellules présentatrices d'antigène ex vivo ou cellules t cd positives activées pour le traitement du cancer
US11325951B2 (en)	2016-09-09	2022-05-10	The General Hospital Corporation	HSP fusion protein with anti-chemorepellant agent for treatment of cancer
WO2018049124A1 (fr)	2016-09-09	2018-03-15	The General Hospital Corporation	Protéine de fusion hsp avec un agent anti-chimiorépulsion pour le traitement d'une maladie infectieuse
WO2018106738A1 (fr)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
US10058573B1 (en)	2017-12-06	2018-08-28	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
IL275077B2 (en) *	2017-12-06	2025-02-01	Magenta Therapeutics Inc	Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
JP7517986B2 (ja) *	2017-12-19	2024-07-17	ジーピーシーアールセラピューティクス，インク．	Ｇｐｃｒヘテロマー阻害剤及びその用途
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en)	2019-10-08	2024-08-13	The Regents Of The University Of California	Methods and compositions for hematopoietic stem cell mobilization
EP4117662A4 (fr)	2020-03-10	2024-04-03	X4 Pharmaceuticals, Inc.	Méthodes de traitement de la neutropénie
EP4146797A1 (fr)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Traitement pour les maladies neurodégénératives
EP4408984A1 (fr)	2021-10-01	2024-08-07	Janssen Pharmaceutica NV	Procédés d'augmentation de la production de cellules progénitrices
WO2025224720A1 (fr)	2024-04-24	2025-10-30	Biolinerx Ltd.	Procédés de sélection de schéma thérapeutique contre des tumeurs solides
CN118987175A (zh) *	2024-08-13	2024-11-22	广东壹加再生医学研究院有限公司	普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US562476A (en) *		1896-06-23		Combined fence-wire reel and straightener
US4111199A (en) *	1977-03-31	1978-09-05	Isaac Djerassi	Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de)	1987-08-24	1989-03-16	Schering Ag	Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr)	1989-03-20	1990-09-21	Centre Nat Rech Scient	Procede de preparation de tetramines cycliques monofonctionnalisees
JP3250220B2 (ja)	1989-10-23	2002-01-28	ニコムドサルターインコーポレーテッド	マルチサイト金属キレート化剤
US5021409A (en)	1989-12-21	1991-06-04	Johnson Matthey Plc	Antiviral cyclic polyamines
US6001826A (en)	1989-12-21	1999-12-14	Anormed, Inc.	Chemical compounds
FR2672051B1 (fr)	1991-01-24	1993-05-21	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en)	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en)	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
DK0670735T3 (da)	1992-11-13	1997-07-28	Univ Washington	Perifisering af hæmotopoietiske stamceller.
GB9400411D0 (en)	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) *	1995-02-02	1995-03-22	Abuljadayel Ilham M S	A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en)	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) *	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) *	1995-06-05	1997-02-25	Nippon Kayaku Co Ltd	末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en)	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
GB9511357D0 (en) *	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US5811544A (en) *	1995-08-28	1998-09-22	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (fr) *	2000-05-09	2001-11-09	The University Of British Columbia	Traitement antagoniste cxcr4 de cellules hematopoietiques
CA2323525C (fr) *	1998-03-30	2011-03-01	Gerald P. Murphy	Applications therapeutiques et diagnostiques basees sur le role du gene cxcr-4 dans l'oncogenese
AU4696899A (en) *	1998-06-19	2000-01-05	General Hospital Corporation, The	Modulating platelet function
CA2244554A1 (fr) *	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition d'une greffe par rapport a la maladie d'un hote
CA2344653A1 (fr)	1998-09-29	2000-04-06	Gamida Cell Ltd.	Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs
JP2002529502A (ja) *	1998-11-17	2002-09-10	スミスクライン・ビーチャム・コーポレイション	血小板減少症の治療法
EP1016413A1 (fr) *	1998-12-30	2000-07-05	Applied Research Systems ARS Holding N.V.	Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes
US6365583B1 (en) *	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
MXPA01009674A (es)	1999-03-24	2003-07-21	Anormed Inc	Compuestos heterociclicos que se unen a receptores de quimiocina.
AU4692400A (en) *	1999-05-03	2000-11-17	Smithkline Beecham Corporation	Cxcr-4 receptor antagonists - thrombopoietin mimetics
CA2389545C (fr) *	1999-12-17	2010-08-31	Anormed Inc.	Recepteur de chemokine liant des composes heterocycliques
AU5811001A (en)	2000-05-09	2001-11-20	Univ British Columbia	Cxcr4 antagonist treatment of hematopoietic cells
CA2412436C (fr) *	2000-06-05	2013-05-21	The Trustees Of Columbia University In The City Of New York	Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
US6734191B2 (en)	2000-09-15	2004-05-11	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
HUP0301094A2 (hu)	2000-09-15	2003-09-29	Anormed Inc.	Kemonikinreceptorhoz kötżdż heterociklusos vegyületek, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
AU2001291569B2 (en)	2000-09-15	2007-07-26	Anormed Inc.	Chemokine receptor binding heterocyclic compounds
NZ524580A (en)	2000-09-29	2004-10-29	Anormed Inc	Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
EP1361851B1 (fr)	2001-01-23	2007-02-21	P & G-Clairol, Inc.	Intermediaires primaires pour coloration capillaire oxydante
CN102302493B (zh)	2001-07-31	2015-08-12	健赞股份有限公司	活化祖细胞/干细胞的方法
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
AU2002357379A1 (en)	2001-12-21	2003-07-15	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de)	2014-03-31	2018-01-18	BSH Hausgeräte GmbH	Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

2002
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 CA CA2455559A patent/CA2455559C/fr not_active Expired - Lifetime
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Ceased
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/fr not_active Revoked
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko not_active Expired - Lifetime
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/fr not_active Withdrawn
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/fr not_active Ceased
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
- 2002-07-30 BR BRPI0211570 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 EP EP02750370A patent/EP1411918B1/fr not_active Revoked
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en not_active Expired - Lifetime
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I2/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I1/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown

Also Published As

Publication number	Publication date
CY2019038I2 (el)	2020-05-29
CY2019038I1 (el)	2020-05-29
LT2371361T (lt)	2019-09-10
US20190216773A1 (en)	2019-07-18
KR20090130152A (ko)	2009-12-17
PT2371361T (pt)	2019-09-10
ES2380009T3 (es)	2012-05-07
IL159312A0 (en)	2004-06-01
US20150246019A1 (en)	2015-09-03
US20060193826A1 (en)	2006-08-31
EP1411918A2 (fr)	2004-04-28
FR12C0042I1 (fr)	2012-08-10
CY1122199T1 (el)	2020-05-29
US6987102B2 (en)	2006-01-17
KR100996378B1 (ko)	2010-11-25
JP2004538303A (ja)	2004-12-24
WO2003011277A3 (fr)	2003-05-22
WO2003011277A2 (fr)	2003-02-13
NL300537I2 (fr)	2017-02-02
US20170049747A1 (en)	2017-02-23
EP3632425A1 (fr)	2020-04-08
MXPA04000982A (es)	2004-04-20
LU92033I2 (fr)	2012-08-27
IL159312A (en)	2015-05-31
CY2012017I1 (el)	2015-08-05
LTC2371361I2 (lt)	2021-09-27
CN102302493B (zh)	2015-08-12
US20130273009A1 (en)	2013-10-17
HK1063005A1 (en)	2004-12-10
NO2020003I1 (no)	2020-03-05
DK1411918T3 (da)	2012-04-23
RU2309741C2 (ru)	2007-11-10
PT1411918E (pt)	2012-03-06
ATE538785T1 (de)	2012-01-15
EP1411918A4 (fr)	2007-11-14
SI2371361T1 (sl)	2019-10-30
RU2004105961A (ru)	2005-03-20
LUC00139I1 (fr)	2019-11-27
DK2371361T3 (da)	2019-08-19
EP2371361A1 (fr)	2011-10-05
HUP0402360A2 (hu)	2005-02-28
FR19C1058I1 (fr)	2019-11-22
NO344632B1 (no)	2020-02-17
NZ530169A (en)	2007-04-27
AU2002318927B2 (en)	2007-01-04
NO2016011I1 (no)	2016-06-10
EP1411918B1 (fr)	2011-12-28
EP2371361B1 (fr)	2019-08-07
ZA200400658B (en)	2005-07-27
JP2008195730A (ja)	2008-08-28
US7897590B2 (en)	2011-03-01
US7935692B2 (en)	2011-05-03
CN1561208A (zh)	2005-01-05
US20030130250A1 (en)	2003-07-10
LUC00139I2 (fr)	2021-02-10
CA2455559C (fr)	2012-01-10
CA2455559A1 (fr)	2003-02-13
CN1561208B (zh)	2010-11-10
ES2742730T3 (es)	2020-02-17
KR20040020075A (ko)	2004-03-06
BR0211570A (pt)	2004-07-13
CY2012017I2 (el)	2015-08-05
BRPI0211570B1 (pt)	2020-01-28
NO20150674A1 (no)	2015-05-27
CY1112633T1 (el)	2015-08-05
SI1411918T1 (sl)	2012-04-30
US20080063624A1 (en)	2008-03-13
LTPA2019018I1 (lt)	2019-12-10
JP5137288B2 (ja)	2013-02-06
NO20040407L (no)	2004-03-19
NO336989B1 (no)	2015-12-14
NL301031I2 (nl)	2020-07-20
FR19C1058I2 (fr)	2020-10-23
NL301031I1 (nl)	2020-02-05
US20060223180A1 (en)	2006-10-05
US20110129448A1 (en)	2011-06-02
BE2019C544I2 (fr)	2021-07-19
BRPI0211570B8 (pt)	2021-05-25
PL364673A1 (en)	2004-12-13
CN102302493A (zh)	2012-01-04

Publication	Publication Date	Title
LUC00139I1 (fr)	2019-11-27
AP1497A (en)	2005-11-20	Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu)	2001-04-28	VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
MXPA05003193A (es)	2005-06-08	Compuesto de adenina novedoso y uso del mismo.
KR930006027A (ko)	1993-04-20	엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
ES2164164T3 (es)	2002-02-16	Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
KR920012082A (ko)	1992-07-25	Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
EA200501148A1 (ru)	2006-04-28	Пиридилоксиметильные и бензизоксазольные азабициклические производные
ATE258050T1 (de)	2004-02-15	Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
ATE46511T1 (de)	1989-10-15	Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
WO1999023092A3 (fr)	1999-08-05	3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
EP1142883A4 (fr)	2002-08-21	Nouveaux composes heterocycliques et compositions de medicaments les renfermant
AR026222A1 (es)	2003-01-29	Compuestos derivados de acido antranilico
MA27576A1 (fr)	2005-10-03	Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
OA09239A (fr)	1992-06-30	"Nouveaux céphèmes et procédés pour leur préparation".
EA200000527A2 (ru)	2000-12-25	Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
WO2007106063A3 (fr)	2007-12-21	Procédés servant à accroître le débit sanguin et/ou à favoriser la régénération d'un tissu
EP1057829A4 (fr)	1999-12-10	Dérivés de la pyrimidine condensés et compositions pharmaceutiques les contenant
EA200001157A2 (ru)	2001-06-25	Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции